クリニカル・トロンボシスと血液静止における人工知能: レビュー
Yi Kiat Isaac Kuan1, Yixin Jamie Kok1, Nigel Sheng Hui Liu2
1Department of Haematology, Tan Tock Seng Hospital, Singapore.
Research and practice in thrombosis and haemostasis
|August 21, 2025
まとめ
人工知能 (AI) と機械学習 (ML) は 血液静止症と血栓症の治療に革命を起こしています これらの技術は診断,リスク評価,パーソナライズされた治療を改善しますが,検証と解釈の難しさは残っています.
科学分野:
- * 医療情報学
- * コンピュータ生物学
- * 血液学
背景:
- * 人工知能 (AI) と機械学習 (ML) は,血静と血栓症の治療にますます適用されています.
- * 適用範囲は診断,リスク評価,実験室検査,患者教育,パーソナライズド医療,医薬品開発などです.
研究 の 目的:
- * 血液静止症と血栓症の治療におけるAIとMLの臨床的有用性と限界をレビューする.
- * この分野における6つの主要な領域におけるAIアプリケーションを探求する.
主な方法:
- * 2025年2月までのPubMed,Embase,Scopusデータベースの包括的な文献検索
- * マニュアルとリファレンスのスクリーニングで補完された,ピアレビューされた英語の研究を含みます.
- * リスク評価,診断,パーソナライズド医療,薬物開発,患者への関与に焦点を当てた84件の研究を分析した.
主要な成果:
- * AIは,画像とEHRデータを用いて高精度で血栓症を診断し,いくつかの感度ギャップを示しています.
- * AIは実験室の誤差検出を改善し,血栓塞栓症リスクの予測において従来のスコアを上回る.
- AIは,パーソナライズされた血液凝固抑制,遺伝的重症の予測,患者教育の強化,新薬の発見を可能にしますが,検証,解釈,バイアスの制限に直面しています.
結論:
- *人工知能は診断,リスク予測,および血栓症と静止症の個別化された治療法の進歩に大きく貢献します.
- * 臨床統合に成功するには,医療のワークフロー内で透明で検証された公平なAIシステムが必要です.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K


